Last updated: September 23, 2026
HAVRIX is a mature hepatitis A vaccine marketed by GSK. Its commercial profile is driven by routine childhood immunization, international travel, public-health vaccination, and outbreak response rather than patent-protected pricing. GSK does not disclose HAVRIX revenue as a standalone line item, so its financial trajectory must be assessed through vaccine-market demand, product positioning, and GSK’s broader vaccines portfolio.
HAVRIX remains commercially relevant, but it is no longer a growth engine comparable with GSK products such as Shingrix and Arexvy. The main financial risks are price competition, procurement pressure, substitution by combination hepatitis A/B vaccines, and the absence of meaningful remaining market exclusivity.
What is HAVRIX and how does it generate revenue?
HAVRIX is an inactivated hepatitis A vaccine containing purified hepatitis A virus antigen. GSK markets pediatric and adult presentations in multiple jurisdictions. The vaccine is administered as a two-dose series, with a booster dose typically given at least six months after the first dose, depending on the applicable national label.
HAVRIX generates revenue through four main channels:
| Revenue channel |
Principal demand driver |
Commercial characteristics |
| Pediatric routine vaccination |
National immunization schedules |
Stable, tender-driven demand |
| Travel vaccination |
International travel and occupational exposure |
Higher private-sector and pharmacy demand |
| Public-health programs |
Outbreaks, homeless populations, high-risk groups |
Episodic volume increases |
| Combination vaccination |
Demand for hepatitis A and B protection |
Competitive pressure from Twinrix and other products |
In the United States, hepatitis A vaccination is recommended for all children beginning at age 12 to 23 months, unvaccinated older children and adolescents, international travelers, and specified high-risk groups. CDC recommendations are a principal demand foundation for HAVRIX and competing hepatitis A vaccines (CDC, 2024).
What is the financial trajectory for HAVRIX?
GSK does not report HAVRIX sales separately in its annual reports. The product is included within the company’s broader vaccines business, which contains substantially larger products and franchises. As a result, public filings do not support a defensible standalone HAVRIX revenue figure or year-over-year growth rate.
The likely financial trajectory is that of a mature, stable-to-low-growth vaccine brand:
- Demand expanded during the long-term adoption of routine hepatitis A vaccination.
- Travel-related demand declined sharply during the COVID-19 travel disruption.
- Travel vaccination recovered as international mobility resumed.
- Public-health campaigns and outbreaks create periodic volume spikes.
- Pricing and market share face pressure from competing vaccines and government tenders.
- Growth is limited because hepatitis A vaccination is well established in major developed markets.
GSK’s vaccine portfolio remains one of its largest business segments, but portfolio-level growth is concentrated in newer or higher-value products. GSK identifies Shingrix, Arexvy, meningitis vaccines, influenza vaccines, and other products as significant contributors to vaccines turnover. HAVRIX is strategically useful as part of the company’s broader vaccine offering but is unlikely to have a material effect on GSK’s consolidated financial results.
What does HAVRIX contribute to GSK’s vaccine portfolio?
HAVRIX contributes through portfolio breadth, established regulatory approvals, manufacturing scale, and access to public-sector and travel-vaccine channels. Its value is greater at the franchise and customer-account level than at the group-revenue level.
HAVRIX can be sold alongside:
- Boostrix and other GSK vaccines in public-health accounts.
- Twinrix for customers seeking hepatitis A and B protection.
- Meningococcal, influenza, and travel vaccines through travel-health providers.
- Pediatric vaccines supplied through government procurement systems.
This portfolio structure can reduce customer-acquisition costs and support bundled tenders, even when HAVRIX itself has limited pricing power.
How large is the hepatitis A vaccine market?
The hepatitis A vaccine market is established and geographically uneven. North America, Western Europe, Japan, Australia, and selected Middle Eastern markets have substantial routine or travel-vaccine demand. Emerging markets have a mixed profile because vaccination policy depends on disease prevalence, sanitation, government budgets, and whether countries use universal or risk-based vaccination.
Market growth is influenced by:
- Rising international travel.
- Government adoption of universal childhood vaccination.
- Hepatitis A outbreaks among adults.
- Vaccination of homeless populations and people who use drugs.
- Expanded immunization in countries transitioning from high to intermediate endemicity.
- Public procurement and donor-supported vaccination programs.
- Supply disruptions affecting competing products.
The commercial market is not uniform. Private travel clinics can support higher realized prices, while government tenders typically impose lower prices and favor dependable supply. This creates a two-tier commercial model: premium private demand and price-sensitive institutional demand.
How do outbreaks affect HAVRIX demand?
Outbreaks can increase short-term demand, especially when public-health authorities conduct targeted campaigns. In the United States, outbreaks associated with person-to-person transmission among adults have periodically increased demand for hepatitis A vaccine.
Outbreak-driven revenue is difficult to forecast because it depends on:
- Geographic concentration.
- Duration of the outbreak.
- Government stockpiling.
- Available doses from all manufacturers.
- Emergency procurement rules.
- Public-health prioritization of high-risk groups.
Outbreaks can create temporary shortages and improve manufacturer volumes, but they do not generally change the long-term pricing structure of a mature vaccine category.
How does HAVRIX compare with competing hepatitis A vaccines?
The principal branded U.S. competitor is VAQTA, marketed by Merck. Twinrix, also marketed by GSK, combines hepatitis A and hepatitis B vaccination and competes with HAVRIX in patients who require protection against both viruses.
| Product |
Company |
Antigens |
Main competitive position |
| HAVRIX |
GSK |
Hepatitis A |
Established monovalent product |
| VAQTA |
Merck |
Hepatitis A |
Direct U.S. branded competitor |
| TWINRIX |
GSK |
Hepatitis A and B |
Combination convenience |
| Regional hepatitis A vaccines |
Multiple manufacturers |
Hepatitis A |
Tender and price competition |
HAVRIX advantages include:
- Long commercial history.
- Broad regulatory familiarity.
- Established pediatric and adult presentations.
- GSK distribution and procurement relationships.
- Integration with GSK’s wider vaccine portfolio.
HAVRIX disadvantages include:
- Mature product economics.
- Limited differentiation from VAQTA.
- Competition from combination vaccination.
- Exposure to government tender pricing.
- Dependence on manufacturing reliability and supply continuity.
The most important product-level competition is not usually a patent-driven generic threat. It is substitution among approved vaccines and procurement-driven share movement.
What is the FDA regulatory status of HAVRIX?
HAVRIX is an FDA-licensed biological product. GSK initially received U.S. approval for HAVRIX in the 1990s, followed by expanded pediatric and adult indications. Current prescribing information governs age ranges, dosing schedules, contraindications, warnings, and administration requirements (FDA, n.d.).
HAVRIX is not a small-molecule drug approved under a conventional abbreviated new drug application. It is regulated as a biologic vaccine under a biologics license application framework.
The principal FDA regulatory issues are:
- Manufacturing consistency.
- Potency and antigen content.
- Sterility and quality control.
- Supply continuity.
- Postmarketing safety monitoring.
- Label changes for schedules and populations.
- Compliance with current good manufacturing practices.
What is the Orange Book status of HAVRIX?
HAVRIX does not rely on a conventional small-molecule Orange Book patent estate. Biologic vaccines historically received market protection primarily through their biologics license, regulatory exclusivity, manufacturing know-how, and product-specific quality controls.
The Biologics Price Competition and Innovation Act created a biosimilar pathway, but it does not create an automatic substitutability or launch pathway equivalent to the mature small-molecule generic market. A competing hepatitis A vaccine would still need to establish its own quality, safety, immunogenicity, and manufacturing profile.
The practical consequence is that HAVRIX can face competition without facing a classic Paragraph IV launch event.
When does HAVRIX lose exclusivity?
HAVRIX’s principal market exclusivity based on originator approval and historical regulatory protection expired long ago. No meaningful remaining market opportunity depends on a near-term patent expiration date.
For a mature vaccine such as HAVRIX, commercial protection comes from:
- Manufacturing process controls.
- Cell-culture and antigen-production expertise.
- Clinical and immunogenicity data.
- Regulatory compliance history.
- Supply contracts.
- Distributor relationships.
- Brand recognition.
- Scale economics.
The absence of a current patent cliff does not eliminate competitive risk. It means the competitive process is gradual and supply-based rather than triggered by a single patent expiration.
Are there Paragraph IV challenges to HAVRIX?
A conventional Paragraph IV challenge is not the central competitive mechanism for HAVRIX. Paragraph IV litigation applies to patents listed in the FDA Orange Book against an abbreviated new drug application. HAVRIX is a biologic vaccine, and a competing product would generally proceed through a biologic or vaccine regulatory pathway rather than a standard ANDA strategy.
No major public Paragraph IV litigation event is associated with HAVRIX’s current commercial position. The relevant challenges are instead:
- Direct competition from VAQTA.
- Competition from Twinrix and regional combination vaccines.
- Public procurement substitution.
- Potential biosimilar or follow-on biologic development.
- Manufacturing and supply constraints.
How strong is the HAVRIX patent estate?
The patent estate is commercially weak as a current exclusivity tool because the product has been marketed for decades. Any foundational composition, formulation, or production patents associated with the original product are likely expired or no longer capable of preventing ordinary market competition.
The stronger barriers are technical and operational:
| Barrier |
Current relevance |
| Composition patents |
Limited because of product age |
| Formulation patents |
Limited unless tied to later improvements |
| Method-of-use patents |
Low commercial importance |
| Manufacturing know-how |
High |
| Regulatory history |
High |
| Quality-control systems |
High |
| Global supply chain |
High |
| Institutional contracts |
Moderate to high |
Manufacturing is particularly important for vaccines because a competitor must produce consistent antigen, demonstrate process control, qualify facilities, and maintain regulatory compliance across jurisdictions.
What formulations and methods of use are protected by HAVRIX?
HAVRIX’s value is tied to its inactivated hepatitis A antigen formulation and approved administration schedule. Public commercial differentiation is limited because the product is used for prevention rather than treatment, and method-of-use patents have little practical importance once routine vaccination schedules are established.
The main regulatory protection relates to the licensed product presentation, manufacturing process, specifications, and approved indications. Historical patents may have covered antigen preparation, purification, stabilization, adjuvant systems, or manufacturing methods, but those protections do not create a substantial current barrier comparable with a live pharmaceutical patent.
What licensing deals affect HAVRIX?
HAVRIX is a GSK-originated and GSK-marketed product. No major current third-party licensing transaction is required to explain its commercial position. The principal strategic relationships are more likely to involve:
- Government procurement agreements.
- Distributor contracts.
- Travel-clinic supply arrangements.
- Regional commercialization agreements.
- Public-health tenders.
GSK’s broader vaccine collaborations and acquisitions can affect manufacturing capacity and portfolio strategy, but public filings do not identify a material standalone licensing stream for HAVRIX.
What patent litigation affects HAVRIX?
HAVRIX has no major current patent-litigation profile comparable with high-revenue small-molecule or biologic products facing imminent generic or biosimilar entry.
Potential disputes would more likely concern:
- Manufacturing technology.
- Vaccine quality and supply.
- Trademark or trade dress.
- Procurement contracts.
- Regulatory exclusivity.
- Follow-on vaccine development.
The absence of major patent litigation reduces legal expense and launch-event risk, but it also confirms that HAVRIX has limited enforceable exclusivity remaining.
What generic or biosimilar launch risks exist for HAVRIX?
The risk of a conventional generic launch is low because HAVRIX is a biological vaccine rather than a conventional small molecule. The risk of competitive replacement is still material.
Potential entrants could include:
- Follow-on hepatitis A vaccines.
- Regional manufacturers with lower-cost products.
- Combination hepatitis A and B vaccines.
- Public-sector suppliers selected through tenders.
- Products produced for emerging markets or international agencies.
A competing product would need to meet demanding manufacturing and regulatory requirements. That creates a higher entry barrier than for many oral generics, but it does not protect HAVRIX from established vaccine competitors.
What is the outlook for HAVRIX revenue?
The base-case outlook is mature and defensive:
| Period |
Likely commercial trend |
Main driver |
| Historical |
Expansion with routine and travel vaccination |
Adoption and disease prevention policy |
| 2020-2021 |
Sharp travel-related disruption |
Reduced international mobility |
| 2022-2024 |
Recovery in travel and private vaccination |
Reopening and resumed travel |
| Near term |
Stable to modest growth |
Routine demand and outbreaks |
| Longer term |
Low growth or gradual erosion |
Tender pricing and product substitution |
HAVRIX revenue is unlikely to grow at the rate of GSK’s newer vaccine franchises. Its financial value lies in recurring demand, relatively predictable clinical use, and contribution to account coverage. Margin performance will depend on manufacturing utilization, procurement mix, raw-material costs, and GSK’s ability to maintain supply without excess capacity.
What is the investment significance of HAVRIX?
HAVRIX is unlikely to be a standalone valuation driver for GSK. The product is more relevant to investors assessing:
- Stability of GSK’s established vaccine base.
- Resilience of travel-health demand.
- Public-health procurement exposure.
- Manufacturing utilization.
- Product portfolio breadth.
- Downside from mature-product pricing.
The key financial distinction is between revenue durability and growth. HAVRIX can remain commercially durable without producing material revenue expansion.
Key Takeaways
- HAVRIX is a mature GSK hepatitis A vaccine with established pediatric, adult, travel, and public-health demand.
- GSK does not disclose standalone HAVRIX revenue, so precise product-level financial growth cannot be calculated from public filings.
- Its financial trajectory is likely stable to low growth after recovery from the COVID-era travel disruption.
- VAQTA is the principal direct branded competitor in the United States.
- Twinrix creates substitution pressure through combined hepatitis A and B coverage.
- HAVRIX does not face a conventional small-molecule generic cliff or material current Paragraph IV threat.
- Historical patent protection is no longer the principal commercial barrier.
- Manufacturing capability, regulatory compliance, supply reliability, and procurement relationships provide the strongest remaining protection.
- Outbreaks can produce short-term demand increases, but they do not transform the long-term category economics.
- HAVRIX is strategically useful to GSK’s vaccines portfolio but is unlikely to be a major standalone growth or valuation driver.
FAQs About HAVRIX Market and Financial Outlook
Is HAVRIX still commercially important to GSK?
Yes, but mainly as a mature portfolio product. Its strategic value comes from recurring demand and portfolio coverage rather than high growth or patent-protected pricing.
Does HAVRIX have a generic equivalent?
There is no conventional generic equivalent in the small-molecule sense. Competing hepatitis A vaccines can enter through biologic and vaccine regulatory pathways, subject to manufacturing and clinical requirements.
Is HAVRIX more profitable than Twinrix?
Public filings do not provide product-level margins. Twinrix may support higher value per vaccination because it combines hepatitis A and B protection, while HAVRIX may benefit from simpler monovalent use and broader routine applications.
Can hepatitis A outbreaks materially increase HAVRIX sales?
Yes. Outbreaks can produce temporary increases in public-health and pharmacy demand, but the effect depends on outbreak duration, government purchasing, available supply, and competition.
Does HAVRIX face biosimilar competition?
A follow-on biological vaccine is theoretically possible, but the practical entry pathway is more complex than a conventional generic launch. Manufacturing consistency, immunogenicity, quality controls, and regulatory requirements are the main barriers.
References
-
Centers for Disease Control and Prevention. (2024). Adult immunization schedule by age and medical condition. https://www.cdc.gov/vaccines/schedules/
-
Centers for Disease Control and Prevention. (2024). Hepatitis A vaccination. https://www.cdc.gov/hepatitis-a/vaccination/
-
GlaxoSmithKline plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/annual-report/
-
U.S. Food and Drug Administration. (n.d.). HAVRIX prescribing information. https://www.fda.gov/vaccines-blood-biologics/vaccines/
-
U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
World Health Organization. (2024). Hepatitis A vaccines: WHO position paper. https://www.who.int/publications/
